Opus Genetics, Inc. IRD 深 滬
已收盤 04-02 16:00:00 美东时间
4.55
-0.140
-2.99%
華盛通- 最 高4.755
- 今 開4.60
- 成交量 34.81万股
- 最 低 4.51
- 昨 收 4.69
- 總市值 3.24亿
- 52周最高 5.30
- 市盈率 靜 --
- 換手率 0.49%
- 52周最低 0.7031
- 委 比 -81.85%
- 總股本 7114.90万
- 歷史最高 23.08
- 量 比 0.77
- 振 幅 5.22%
- 歷史最低 0.65
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Cantor Fitzgerald Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $15
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Opus Genetics (NASDAQ:IRD) with a Overweight rating and announces Price Target of $15.
03-30 19:19
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $10
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $8 to $10.
03-12 20:23
Earnings Summary: Opus Genetics Q4
The earnings results for Opus Genetics (NASDAQ:IRD) for Q4 were made public on ...
03-10 19:26
Opus Genetics Q4 EPS $(0.21) Misses $(0.12) Estimate, Sales $3.865M Beat $3.649M Estimate
Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.12) by 70.73 percent. This is a 83.46 percent increase over losses of $(1.27) per share from
03-10 19:26
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Where Opus Genetics Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
03-02 21:00
Opus Genetics Reveals New Clinical Data From Its Ongoing Phase 1/2 Study Of OPGx-BEST1 Gene Therapy; Sentinel Participant Showed OPGx-BEST1 Was Well Tolerated With No Ocular Inflammation, Treatment-related Adverse Events, Or Dose-limiting Toxicities At Three Months;
Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal
02-27 23:13
